Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | SLS SELLAS Life Sciences Group, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $12.31 +7.0% | $16.31 +6.3% |
| StockIQ Score | 54C- Moderate Risk: Medium | 42D Weak Risk: Medium |
| Technical | 50C- | 36F |
| Fundamental | 46D+ | 35F |
| Growth | 63C+ | 50C- |
| Fair Value | 50C- | 38F |
| News | 86A | 50C- |
| Quality | 42D | 50C- |
| Risk | 48D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
SLS outperforms AAPG across most categories. Its investor score (54 vs. 42) and growth score (63 vs. 50) are notably stronger, reflecting better investor confidence and growth potential. SLS also has a higher fundamental score (46 vs. 35), while AAPG’s weak rating and lower technical and valuation scores (36 vs. 50 and 38 vs. 50) suggest more risk.
